The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.

Polyzois Makras Natasha M Appelman-DijkstraSocrates E PapapoulosSandra van WissenElizabeth M WinterStergios A PolyzosMaria P YavropoulouAthanasios D Anastasilakis

Published in: The Journal of clinical endocrinology and metabolism (2021)

The duration of denosumab treatment significantly affects the efficacy of subsequent zoledronate infusion to maintain BMD gains. Frequent follow-up of patients treated with denosumab longer than 3 years is advisable as additional therapeutic interventions may be needed.

Keyphrases

bone mineral density
postmenopausal women
body composition
giant cell
low dose
combination therapy
smoking cessation